IP Library Granted Patent US 12,474,333
Granted Patent B2
US 12,474,333 · App. 17/343,490 · Granted Nov 18, 2025

Interactive test system and method for detecting an analyte

Inventors: Rhys L. de Callier (San Marcos, CA); Richard L. Egan (Oceanside, CA); William J. Ferenczy (La Jolla, CA); Michael Jon Hale (San Diego, CA)
Assignee: Ortho-Clinical Diagnostics, Inc.
G01N33/54388G01N33/5302G01N33/585
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,474,333
App. No.
17/343,490
Granted
Nov 18, 2025
Kind
B2
Abstract

A system comprised of an apparatus and a test device is described. The test device and the apparatus are designed to interact to determine the presence or absence of an analyte of interest in a sample placed on the test device. The test device and apparatus interact to provide a timer feature for determining a test device specific adjustable cut-off value that is used to ascertain whether signal from a test line in the device corresponds to a positive or negative results, irrespective of the time elapsed since placement of sample on the test device. The adjustable cut-off value renders the system relatively insensitive to incubation time of the test device, where if the incubation time is shorter or longer than needed for accuracy of a test result, the analyzer will report an invalid result, thus preventing the reporting of an incorrect (false negative or false positive) result.

Claims (33)

1 . A system, comprising:

a test device comprising:

(a) a label zone comprising

(i) a first population of mobilizable, detectable particles for specific binding to a test analyte in a sample; and

(ii) a second population of mobilizable, detectable particles for specific binding to a non-test analyte but not to the test analyte;

(b) a first detection site at a first position comprising a first binding member having specific binding affinity for detectable particles in the first population bound to the test analyte; and

(c) a second detection site at a second position that is separate from the first position, the second detection site comprising a second binding member having specific binding affinity for detectable particles in the second population bound to the non-test analyte; and

an analyzer comprising:

(1) an opening dimensioned to receive the test device,

(2) an optical system for detection of a signal generated from the first population of mobilizable, detectable particles at the first position and the second population of mobilizable, detectable particles at the second position when each population reaches a specific and separate position on the test device,

(3) a processor communicatively coupled with the optical system to receive the signal and to evaluate a ratio of a signal detected from all or a portion of the first population of mobilizable, detectable particles to a cut-off value to determine a presence or an absence of analyte in the sample based on the ratio, and

(4) a memory storing the cut-off value, wherein the cut-off value is an exponentially transformed signal from all or a portion of the second population of mobilizable, detectable particles, adjusted by an empirically determined constant value for a manufacturing lot comprising the test device.

2 . The system of claim 1 , wherein the signal from all or a portion of the first population of mobilizable, detectable particles is used by the processor to provide a quantitative or semi-quantitative amount of analyte present in the sample.

3 . The system of claim 1 , wherein signal from the second population of mobilizable, detectable particles is mathematically transformed by the processor in the analyzer to provide a transformed signal.

4 . The system of claim 3 , wherein the signal from the second population of mobilizable, detectable particles is mathematically transformed by the processor using an exponential transformation.

5 . The system of claim 4 , wherein the exponential transformation is selected from an exponential value of between 1.3-1.8.

6 . The system of claim 5 , wherein transformed signal is multiplied by a constant value specific for an analyte to yield a transformed cut-off value.

7 . The system of claim 6 , wherein the constant value is determined for each specific manufacturing lot of analyte.

8 . The system of claim 1 , wherein the test device is a lateral flow immunoassay.

9 . The system of claim 8 , wherein one or both of the first population of mobilizable, detectable particles and the second population of mobilizable, detectable particles is comprised of particles comprised of a fluorescing lanthanide compound.

10 . The system of claim 9 , wherein the fluorescing lanthanide compound is europium.

11 . A method for determining presence or absence of an analyte in a sample, comprising:

depositing a sample on a test device comprising a first population of detectable particles for detection of an analyte in a sample and a second population of detectable particles for specific binding to a non-test analyte,

inserting the test device into an analyzer capable of receiving the test device, the analyzer comprising an optical system for detection of a signal generated from each of the first and second populations of particles when each population reaches a specific position on the test device,

detecting an intensity of signal from all or a portion of the second population of particles;

calculating a cut-off value used in an algorithm in the analyzer to determine whether the signal from all or a portion of the first population of particles corresponds to the presence or absence of analyte in the sample, wherein said calculating comprises calculating a transformed cut-off value by exponentiation of the signal from all or a portion of the second population of particles, and comparing the transformed cut-off value by signal from all or a portion of the first population of particles; and

reporting a result from the calculating.

12 . The method of claim 11 , wherein the analyte of interest is a protein.

13 . The method of claim 12 , wherein the protein in human chorionic gonadotropin.

14 . The method of claim 12 , wherein the analyte of interest is an infectious analyte.

15 . The method of claim 14 , wherein the infectious analyte is a virus or a bacteria.

16 . The method of claim 15 , wherein the infectious analyte is influenza A or influenza B.

17 . The method of claim 11 , wherein the exponent in the exponentiation is between 1.2-1.8.

Assignments (5)
SECURITY AGREEMENT Recorded Aug 22, 2025
From: CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; QUIDEL CARDIOVASCULAR INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 072526/0643 →
RELEASE (REEL 060220 / FRAME 0711) Recorded Aug 22, 2025
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
Reel/Frame 072577/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2024
From: QUIDEL CORPORATION
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 068657/0827 →
SECURITY AGREEMENT Recorded May 31, 2022
From: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 060220/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2021
From: DE CALLIER, RHYS; EGAN, RICHARD L.; FERENCZY, WILLIAM J.; HALE, MICHAEL JON
To: QUIDEL CORPORATION
Reel/Frame 056553/0041 →
Continuity (6)
Continuation 13783065 · Mar 1, 2013
Provisional Application 61757023 · Jan 25, 2013
Provisional Application 61666689 · Jun 29, 2012
Provisional Application 61636105 · Apr 20, 2012
Provisional Application 61605694 · Mar 1, 2012
Related Publication 20210293793A1 · Sep 23, 2021
References Cited (86)
US 4934817A · Gassenhuber · 1990 [cited by applicant]
US 5204264A · Kaminer et al. · 1993 [cited by applicant]
US 5238737A · Burkhardt et al. · 1993 [cited by applicant]
US 5414258A · Liang · 1995 [cited by applicant]
US 5766961A · Pawlak · 1998 [cited by applicant]
US 5770460A · Pawlak et al. · 1998 [cited by applicant]
US 6074616A · Buechler et al. · 2000 [cited by applicant]
US 6136610A · Polito et al. · 2000 [cited by applicant]
US 6144455A · Tuunanen et al. · 2000 [cited by applicant]
US 6267722B1 · Anderson et al. · 2001 [cited by applicant]
US 6392894B1 · Buechler et al. · 2002 [cited by applicant]
US 6394952B1 · Anderson et al. · 2002 [cited by applicant]
US 6727073B1 · Moore et al. · 2004 [cited by applicant]
US 6830731B1 · Buechler et al. · 2004 [cited by applicant]
US 6867051B1 · Anderson et al. · 2005 [cited by applicant]
US 6878947B2 · Haberstroh · 2005 [cited by applicant]
US 6936476B1 · Anderson et al. · 2005 [cited by applicant]
US 7002688B2 · Aravanis et al. · 2006 [cited by applicant]
US 7437913B2 · Djennati et al. · 2008 [cited by applicant]
US 7521249B2 · Rosen et al. · 2009 [cited by applicant]
US 7521260B2 · Petruno et al. · 2009 [cited by applicant]
US D606664S · Jacono et al. · 2009 [cited by applicant]
US 7632687B2 · Gokhan · 2009 [cited by applicant]
US 7784679B2 · Kuo et al. · 2010 [cited by applicant]
US 7925445B2 · Petrilla et al. · 2011 [cited by applicant]
US 8039783B2 · Lai · 2011 [cited by applicant]
US 8043867B2 · Petruno et al. · 2011 [cited by applicant]
US 8128871B2 · Petruno et al. · 2012 [cited by applicant]
US 8334522B2 · Egger · 2012 [cited by applicant]
US 9207181B2 · Egan et al. · 2015 [cited by applicant]
US 10281462B2 · Egan et al. · 2019 [cited by applicant]
US 11061020B2 · De Callier et al. · 2021 [cited by applicant]
US 11131666B2 · Egan et al. · 2021 [cited by applicant]
US 20020190356A1 · Buechler et al. · 2002 [cited by applicant]
US 20040018637A1 · Polito et al. · 2004 [cited by applicant]
US 20040241047A1 · Buechler et al. · 2004 [cited by applicant]
US 20050017076A1 · Hosokawa et al. · 2005 [cited by applicant]
US 20050239213A1 · Stephens · 2005 [cited by examiner]
US 20060008538A1 · Anderson et al. · 2006 [cited by applicant]
US 20060228554A1 · Tan et al. · 2006 [cited by applicant]
US 20070154970A1 · Buechler et al. · 2007 [cited by applicant]
US 20070236692A1 · Schebesta et al. · 2007 [cited by applicant]
US 20080031779A1 · Polito et al. · 2008 [cited by applicant]
US 20080081341A1 · Maher et al. · 2008 [cited by applicant]
US 20080081376A1 · Hernandez et al. · 2008 [cited by applicant]
US 20080199851A1 · Egan et al. · 2008 [cited by applicant]
US 20080311002A1 · Kirby et al. · 2008 [cited by applicant]
US 20090061507A1 · Ho · 2009 [cited by applicant]
US 20090090874A1 · Roper et al. · 2009 [cited by applicant]
US 20090142856A1 · Hudak et al. · 2009 [cited by applicant]
US 20090263854A1 · Jacono et al. · 2009 [cited by applicant]
US 20100068826A1 · Gokhan · 2010 [cited by applicant]
US 20100117003A1 · Egger · 2010 [cited by applicant]
US 20100135857A1 · Hunter et al. · 2010 [cited by applicant]
US 20100311181A1 · Abraham et al. · 2010 [cited by applicant]
US 20110043618A1 · Salisbury et al. · 2011 [cited by applicant]
US 20120021531A1 · Ellis et al. · 2012 [cited by applicant]
US 20120071342A1 · Lochhead et al. · 2012 [cited by applicant]
US 20120223251A1 · Morrow et al. · 2012 [cited by applicant]
US 20120300205A1 · Misener et al. · 2012 [cited by applicant]
US 20130230844A1 · Egan et al. · 2013 [cited by applicant]
US 20130230845A1 · Egan et al. · 2013 [cited by applicant]
US 20160054316A1 · Egan et al. · 2016 [cited by applicant]
US 20190271695A1 · Egan et al. · 2019 [cited by applicant]
US 20210293793A1 · Egan et al. · 2021 [cited by applicant]
US 20210389316A1 · Egan et al. · 2021 [cited by applicant]
CN 2653511Y · 2004 [cited by applicant]
CN 1766580A · 2006 [cited by applicant]
CN 101598861A · 2009 [cited by applicant]
EP 0174722A2 · 1986 [cited by applicant]
JP 2003083970A · 2003 [cited by applicant]
WO WO1999039298A1 · 1999 [cited by applicant]
WO WO2000031539A1 · 2000 [cited by applicant]
WO WO2005031355A1 · 2005 [cited by applicant]
WO WO2009014787A2 · 2009 [cited by applicant]
WO WO2010081219A1 · 2010 [cited by applicant]
WO WO2013131052A1 · 2013 [cited by applicant]
WO WO2013131057A1 · 2013 [cited by applicant]
Newberry, Michael. “Tech Note: Pixel Response Effects on CCD Camera Gain Calibration.” (1996). Mirametrics, Inc., https://www.mirametrics.com/tech_note_ccdgain.php. Accessed: Mar. 11, 2025. (Year: 1996). [cited by examiner]
Ahn et al., “Development of a point-of-care assay system for high-sensitivity C-reaction protein in whole blood”, Clinica Chimica Acta, vol. 332. pp. 51-59 (2003). [cited by applicant]
Egan et al., “High sensitivity immunofluorescence influenza A+B assay with reader”, 27 [cited by applicant]
Giebeler et al., “Performance validation for microplate fluorimeters”, vol. 15, No. 3, pp. 363-375 (2005). [cited by applicant]
International Search Report from PCT Patent Application No. PCT/US2013/028743 mailed May 28, 2013. [cited by applicant]
International Search Report from PCT Patent Application No. PCT/US2013/028749 mailed Jul. 1, 2013, application now published as PCT Publication No. WO2013/131057 on Sep. 6, 2013. [cited by applicant]
International Search Report from PCT Patent Application No. PCT/US2014/068829 mailed Mar. 6, 2015. [cited by applicant]
Van Dyke et al., “Multiplex point of care (POC) assay for the detection community acquired resoiratory viruses”, 27 [cited by applicant]